Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH, Miller VA
Clin Cancer Res. 2007 13 (17): 5150-5

PMID: 17785570 · DOI:10.1158/1078-0432.CCR-07-0560

MeSH Terms (22)

Adult Aged Aged, 80 and over Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Carcinoma, Non-Small-Cell Lung Drug Resistance, Neoplasm Erlotinib Hydrochloride Everolimus Female Fluorodeoxyglucose F18 Gefitinib Humans Lung Neoplasms Male Middle Aged Positron-Emission Tomography Prospective Studies Protein Kinase Inhibitors Quinazolines Sirolimus Tomography, X-Ray Computed

Connections (1)

This publication is referenced by other Labnodes entities: